Research and analysis

ACRE advice: camelina trial

The advice of the Advisory Committee on Releases to the Environment on the release of genetically modified camelina.

• From: Advisory Committee on Releases to the Environment
• Published: 10 April 2014
• Last updated: 9 May 2019 — See all updates

Documents

ACRE advice on GM Camelina (19/R08/01)

PDF, 140 KB, 8 pages

ACRE advice on GM Camelina (18/R08/01)

PDF, 152 KB, 6 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

ACRE advice on GM Camelina (16/R8/01)

PDF, 206 KB, 10 pages

ACRE advice on GM Camelina (14/R8/01)

PDF, 209 KB, 8 pages

Advice on genome-edited Camelina plants with increased levels of oleic acid

PDF, 143 KB, 3 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

These documents are the advice of the Advisory Committee on Releases to the Environment (ACRE) to government on an application from Rothamsted Research to carry out a trial of Camelina sativa, which has been genetically modified to produce omega-3 fatty acids in its seed oil.

The committee advised that the risks to human health and the environment from this trial are extremely low.

Published 10 April 2014
Last updated 9 May 2019 + show all updates

1. 9 May 2019

   Added the advice on an application for a trial of GM camelina (19/R08/01).

2. 21 April 2016

   Added ACRE advice on GM Camelina (16/R8/01).

3. 10 April 2014

   First published.